SecBot SecBot
425 ·Filed Jun 8, 2026

LAB

STANDARD BIOTOOLS INC.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001104659-26-071198
Rule 425 M&A communications
Actionable Insight ▲ Bullish

The merger is transformative, turning LAB into a clinical-stage biotech with a promising pipeline. LAB shareholders should evaluate the combined company's prospects and the potential value of CVRs. Monitor stockholder vote and regulatory milestones (HSR). The deal structure suggests significant dilution for current LAB holders, but the Treeline pipeline may drive long-term value.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8032
T+0 close · Jun 8, 2026 · via day close
Latest settled
−19.01%
T+60 · $0.6505
Vs SPY
−22.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $0.8032entry
  2. T+1 · 5mo ago +10.33%α +10.63% · $0.8862
  3. T+5 · 5mo ago +5.63%α +3.52% · $0.8484
  4. T+20 · 4mo ago +10.47%α +8.84% · $0.8873
  5. T+60 · 3mo ago −19.01%α −22.06% · $0.6505
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools (LAB) announced a transformative all-stock reverse merger with private biotech Treeline Biosciences. Treeline is valued at $2.5 billion, while LAB's net cash implies an equity value of ~$460 million. Former Treeline stockholders will own ~84% of the combined company on a fully diluted basis, with LAB holders retaining ~16%. LAB also plans to issue CVRs to its stockholders tied to monetization of its legacy businesses, capped at 76 million shares. The deal requires LAB stockholder approval and is expected to close in H2 2026.

Key Financial Metrics

Deal Value
$2.5B
Deal Type
merger

Key Facts

  • All-stock reverse merger with Treeline Biosciences valued at $2.5B.
  • LAB implied equity value of ~$460M based on net cash at closing.
  • Former Treeline stockholders to own ~84% of combined company; LAB holders ~16%.
  • CVRs to be issued to LAB stockholders, capped at 76M shares, tied to legacy business monetization.
  • Closing expected in H2 2026, subject to LAB stockholder approval and regulatory clearances.

Financial Impact

Treeline valued at $2.5B, LAB equity valued at ~$460M, combined ~$2.96B. LAB shareholders' 16% stake valued at ~$474M vs current market cap of $449M, implying a modest premium. CVRs provide additional contingent value.

valuationownership_structurecontingent_value_rights

Risk Factors

  • Stockholder approval required; potential opposition or competing proposals.
  • Regulatory approvals (HSR) and other closing conditions.
  • Integration risks and uncertainty around Treeline's pipeline development.
  • CVR value depends on legacy business monetization, which may not materialize.

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
67% bullish (6 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001104659-26-071198
Document: tm2617100d2_ex10-3.htm0001104659-26-071198
Document: tm2617100d2_ex10-1.htm0001104659-26-071198
Document: tm2617100d2_425.htm0001104659-26-071198
Document: tm2617100d2_ex99-2.htm0001104659-26-071198

Track record

23 reports on LAB

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026